(Q50753687)

18 March 2018

title

Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients. (English)

1 reference

18 March 2018

triple-negative breast cancer

main subject

1 reference

Minghui Zhang

1

1 reference

18 March 2018

Xiaosan Zhang

2

1 reference

18 March 2018

Shu Zhao

3

1 reference

18 March 2018

Yan Wang

4

1 reference

18 March 2018

Wenyu Di

5

1 reference

18 March 2018

Gangling Zhao

6

1 reference

18 March 2018

Maopeng Yang

7

1 reference

18 March 2018

Qingyuan Zhang

8

1 reference

18 March 2018

publication date

1 December 2014

1 reference

18 March 2018

published in

Targeted oncology

1 reference

18 March 2018

volume

9

1 reference

18 March 2018

issue

4

1 reference

18 March 2018

page(s)

349-357

1 reference

18 March 2018

Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0300-Y

'Triple negative' breast cancer: a new area for phase III breast cancer clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0300-Y

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0300-Y

Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0300-Y

Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0300-Y

Lack of prognostic significance of survivin, survivin-deltaEx3, survivin-2B, galectin-3, bag-1, bax-alpha and MRP-1 mRNAs in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0300-Y

Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0300-Y

Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0300-Y

Survivin study: an update of "what is the next wave"?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0300-Y

Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0300-Y

Survivin expression in hepatocellular carcinoma: correlation with proliferation, prognostic parameters, and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0300-Y

Survivin and epidermal growth factor receptor expression in surgically treated oropharyngeal squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0300-Y

Prognostic importance of survivin in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0300-Y

Fragile histidine triad protein, WW domain-containing oxidoreductase protein Wwox, and activator protein 2gamma expression levels correlate with basal phenotype in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0300-Y

Survivin expression in oral squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0300-Y

Immunohistochemical study of androgen receptors in breast carcinoma. Evidence of their frequent expression in lobular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0300-Y

Molecular biology in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0300-Y

The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0300-Y

Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0300-Y

High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0300-Y

Impact of EGFR expression on colorectal cancer patient prognosis and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0300-Y

Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0300-Y

EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0300-Y

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0300-Y

Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0300-Y

Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0300-Y

The molecular basis and potential role of survivin in cancer diagnosis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0300-Y

EGFR enhances Survivin expression through the phosphoinositide 3 (PI-3) kinase signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0300-Y

Expression of cytoplasmic and nuclear Survivin in primary and secondary human glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0300-Y

A conserved family of cellular genes related to the baculovirus iap gene and encoding apoptosis inhibitors

21 January 2018

1 reference

12 December 2020

Survivin is an independent prognostic marker for risk stratification of breast cancer patients

1 reference

12 December 2020

EGFR expression in urothelial carcinoma of the upper urinary tract is associated with disease progression and metaplastic morphology

1 reference

12 December 2020

Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters.

1 reference

12 December 2020

Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer

1 reference

12 December 2020

Epithelial growth factor receptor status in primary and recurrent ovarian cancer

1 reference

12 December 2020

Androgen Receptor Expression in Estrogen Receptor-Negative Breast Cancer Immunohistochemical, Clinical, and Prognostic Associations

1 reference

12 December 2020

Epidermal growth factor receptor protein expression and gene amplification in small cell carcinoma of the urinary bladder

1 reference

12 December 2020

High survivin predicts a poor response to endocrine therapy, but a good response to chemotherapy in advanced breast cancer

1 reference

12 December 2020

Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder.

1 reference

12 December 2020

Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration

1 reference

12 December 2020

Survivin--a universal tumor antigen

1 reference

12 December 2020

Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis

1 reference

12 December 2020

Expression of survivin and its relationship to loss of apoptosis in breast carcinomas

1 reference

12 December 2020

Does the epidermal growth factor receptor play a role in the progression of thyroid cancer?

1 reference

12 December 2020

Prognosis of glioma patients by combined immunostaining for survivin, Ki-67 and epidermal growth factor receptor

1 reference

12 December 2020

10.1007/S11523-013-0300-Y

Identifiers

DOI

1 reference

18 March 2018

1 reference

18 March 2018